Shares of T2 Biosystems Inc (NASDAQ:TTOO) saw unusually-high trading volume on Wednesday . Approximately 849,941 shares changed hands during trading, an increase of 375% from the previous session’s volume of 178,795 shares.The stock last traded at $4.20 and had previously closed at $4.19.

TTOO has been the topic of a number of research reports. ValuEngine raised shares of T2 Biosystems from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Zacks Investment Research raised shares of T2 Biosystems from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. HC Wainwright initiated coverage on shares of T2 Biosystems in a report on Wednesday, October 18th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Canaccord Genuity reissued a “buy” rating and issued a $6.00 price target on shares of T2 Biosystems in a report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $6.54.

The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.28 and a current ratio of 5.40.

T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. The firm had revenue of $1.11 million for the quarter, compared to analyst estimates of $1.10 million. T2 Biosystems had a negative net margin of 1,497.70% and a negative return on equity of 244.82%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. equities analysts expect that T2 Biosystems Inc will post -1.85 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. LMR Partners LLP bought a new stake in T2 Biosystems in the 2nd quarter valued at $180,000. Susquehanna International Group LLP boosted its stake in shares of T2 Biosystems by 931.3% in the 2nd quarter. Susquehanna International Group LLP now owns 85,620 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 95,920 shares in the last quarter. Gagnon Securities LLC acquired a new stake in shares of T2 Biosystems in the 3rd quarter valued at $396,000. Point72 Asset Management L.P. acquired a new stake in shares of T2 Biosystems in the 3rd quarter valued at $630,000. Finally, Essex Investment Management Co. LLC boosted its stake in shares of T2 Biosystems by 239.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 706,194 shares of the medical equipment provider’s stock valued at $2,966,000 after purchasing an additional 498,004 shares in the last quarter. 59.73% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/21/t2-biosystems-ttoo-sees-unusually-high-trading-volume.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.